How a ‘Rule of Two’ could remove our barrier to better drug access
When a new pharmaceutical is so successful that it blows out the national income accounts, it’s probably safe to call it a wonderdrug. Semaglutide, marketed as Ozempic when treating Type II diabetes and as Wegovy for weight loss, turned a half-year 0.3% decline in Danish GDP into a 1.7% year-on-year increase. Read more